PDF herunterladen
Arzneimittelforschung 2009; 59(7): 345-349
DOI: 10.1055/s-0031-1296406
Antiallergic Drugs · Antiasthmatics · Antitussives · Bronchodilators · Bronchosecretogogues · Mucolytics
Editio Cantor Verlag Aulendorf (Germany)

Bioequivalence of Fexofenadine Tablet Formulations Assessed in Healthy Iranian Volunteers

Hadi Valizadeh
Department of Pharmaceutics, Faculty of Pharmacy, Tabriz University of Medical Sciences, Tabriz, Iran
Research Center for Pharmaceutical Nanotechnology, Tabriz University of Medical Sciences, Tabriz, Iran
,
Barghi Leila
Drug Applied Research Center, Tabriz University of Medical Sciences, Tabriz, Iran
,
Hadi Jalilian
Department of Pharmaceutics, Faculty of Pharmacy, Tabriz University of Medical Sciences, Tabriz, Iran
,
Ziba Islambulchilar
Department of Pharmaceutics, Faculty of Pharmacy, Zanjan University of Medical Sciences, Zanjan, Iran
,
Parvin Zakeri-Milani
Department of Pharmaceutics, Faculty of Pharmacy, Tabriz University of Medical Sciences, Tabriz, Iran
Biotechnology Research Center, Tabriz University of Medical Sciences, Tabriz, Iran
› Institutsangaben
Weitere Informationen

Publikationsverlauf

Publikationsdatum:
13. Dezember 2011 (online)

    Lizenzen und Reprints

Key words

Antihistaminic drugs - CAS 153439-40-8 - Fexofenadine, bioavailability, bioequivalency, HPLC, pharmacokinetics
 

  • References

  • 1 Isleyen EAÖ, Özden T, Toptan S. Quantitative Determination of Fexofenadine in Human Plasma by HPLC-MS. Chromatographia. 2007; 66: 109-13
    CrossrefPubMedGoogle Scholar
  • 2 Hofmann U, Seiler M, Drescher S, Fromm MF. Determination of fexofenadine in human plasma and urine by liquid chromatography-mass spectrometry. J Chromatogr B Analyt Technol Biomed Life Sci. 2002; 766 (2) 227-33
    CrossrefPubMedGoogle Scholar
  • 3 Ujie K, Oda M, Kobayashi M, Saitoh H. Relative contribution of absorptive and secretory transporters to the intestinal absorption of fexofenadine in rats. Int J Pharm. 2008; 361: 7-11
    CrossrefPubMedGoogle Scholar
  • 4 Sweetman SC. Martindale: The Complete Drug Reference. London: The Pharmaceutical Press; 2007
    Google Scholar
  • 5 Chen C. Some pharmacokinetic aspects of the lipophilic terfenadine and zwitterionic fexofenadine in humans. Drugs RD. 2007; 8 (5) 301-14
    CrossrefPubMedGoogle Scholar
  • 6 Peng SX, Ritchie DM, Cousineau M, Danser E, Dewire R, Floden J. Altered oral bioavailability and pharmacokinetics of P-glycoprotein substrates by coadministration of bio-chanin A. J Pharm Sei. 2006; 95 (9) 1984-93
    CrossrefPubMedGoogle Scholar
  • 7 Perloff MDP, von Moltke LLMD, Greenblatt DJMD. Fexofenadine Transport in Caco-2 Cells: Inhibition with Verapamil and Ritonavir. J Clin Pharmacol. 2002; 42 (11) 1269-74
    PubMedGoogle Scholar
  • 8 Miura M, Uno T, Tateishi T, Suzuki T. Pharmacokinetics of fexofenadine enantiomers in healthy subjects. Chirality. 2007; 19 (3) 223-7
    CrossrefPubMedGoogle Scholar
  • 9 Banfield C, Gupta S, Marino M, Lim J, Affrime M. Grapefruit juice reduces the oral bioavailability of fexofenadine but not desloratadine. Clin Pharmacokinet. 2002; 41 (4) 311-8
    CrossrefPubMedGoogle Scholar
  • 10 Zakeri-Milani P, Valizadeh H, Islambulchilar Z. Comparative bioavailability study of two Cefixime formulations administered orally in healthy male volunteers. Arzneimittelforschung. 2008; 58 (2) 97-100
    Artikel in Thieme ConnectPubMedGoogle Scholar
  • 11 Surapaneni S, khalil SKW. A sensitive HPLC method for the determination of terfenadine and its metabolite in human plasma. J Liquid Chromatogr. 1994; 17 (11) 2419-28
    CrossrefPubMedGoogle Scholar
  • 12 Coutant JE, Westmark PA, Nardella PA, Marc Walter S, Okerholm RA. Determination of terfenadine and terfenadine acid metabolite in plasma using solid-phase extraction and high-performance liquid chromatography with fluorescence detection. J Chromatogr. 1991; 570 (1) 139-48
    CrossrefPubMedGoogle Scholar